Media

PRESS

e-NICOTINE TECHNOLOGY’S EXECUTIVE MANAGEMENT TEAM LEADING TALKS ON INNOVATION IN NICOTINE DELIVERY AT A WIDE VARIETY OF REGULATORY AND INDUSTRY CONFERENCES

Published: 2014-04-29

SALT LAKE CITY, UT (April 29, 2014) – e-Nicotine Technology (eNT) today announced that members of its executive management team will be speaking at a variety of important industry conferences this spring, including: the FDA’s Center for Tobacco Products Tobacco Products Scientific Advisory Committee (TPSAC) meeting on April 16th (Rockville, MD), the Tobacco Merchants Association on May 21st (Williamsburg, VA), and the e-Cig Conference on June 18th (Nice, France).

 

To review Michael Hufford’s presentation from the TPSAC meeting on April 16, 2014 please click here or download the press release.


view pdf

 

e-NICOTINE TECHNOLOGY TO BRING ELECTRONIC NICOTINE DELIVERY PRODUCTS TO MARKET TO ADDRESS KEY UNMET NEEDS FOR SMOKERS AND THE PUBLIC HEALTH COMMUNITY

Published: 2014-03-10

CHAPEL HILL, NC (March 10, 2014) – e-Nicotine Technology (eNT) today announced details regarding its family of products aimed at helping smokers as they transition off of combustible cigarettes. Having recently completed clinical trials in nearly 100 smokers and showing rapid (within 1-minute), dramatic (up to 83% reduction) and sustained smoking urge reduction, eNT is moving forward toward the launch of its family of state-of-the-art electronic nicotine delivery products.


view pdf

 

eNT Shows Significant Reductions In Smoking Urge

Published: 2014-02-12

CHAPEL HILL, NC  (February 14, 2014) – e-Nicotine Technology (eNT) announced details from its initial clinical trial that were presented last week at the 20th Annual Meeting of the Society for Research on Nicotine and Tobacco in Seattle, WA. The data were part of a presentation entitled  “Achieving Rapid Smoking Urge Relief and Nicotine Pharmacokinetics Through the Manipulation of the Particle Size of a Condensation Aerosol of Nicotine and Propylene Glycol.” The clinical trial tested eNT’s proprietary nicotine delivery system in a group of 77 dependent smokers that had not set a goal to quit smoking. eNT’s 50, 75, and 100 mcg nicotine dose groups all reported significant (p<.01) reductions in their median percent smoking urge (75%, 70%, and 83%, respectively) at 1-minute after dosing, which were sustained over time. Fully 75% of subjects reported that they would use the 50 mcg nicotine aerosol as a substitute for their smoking.


view pdf

 

e-NICOTINE TECHNOLOGY TO PRESENT CLINICAL DATA AT THE SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

Published: 2014-01-30

CHAPEL HILL, NC  (January 31, 2014) – e-Nicotine Technology (eNT) announced today that it will be presenting its initial clinical research results in a poster entitled “Achieving Rapid Smoking Urge Relief and Nicotine Pharmacokinetics Through the Manipulation of the Particle Size of a Condensation Aerosol of Nicotine and Propylene Glycol” at the 20th Annual Meeting for the Society for Research on Nicotine and Tobacco being held from February 5-8th this year in Seattle, WA.


view pdf